The goal of this study is to evaluate how safe and effective the new study drug BIIB122 is for the treatment of participants with early stage Parkinson’s disease. The study compares the effect of the study drug BIIB122 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

30-80 years

Early stage Parkinson's disease

55 to 151 weeks

Amsterdam and Zwolle

The goal of this study is to evaluate how safe and tolerable the investigational study drug selnoflast is for the treatment of participants with early stage Parkinson’s disease (with slowness of movement, and resting tremor or rigidity). The study compares the effect of selnoflast with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

40-85 years

Parkinson's disease

14 weeks

Amsterdam and Zwolle